Collegium Pharmaceutical (NASDAQ:COLL) Given New $48.00 Price Target at Truist Financial

Collegium Pharmaceutical (NASDAQ:COLL) had its target price upped by equities researchers at Truist Financial from $45.00 to $48.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target would suggest a potential upside of 12.09% from the stock’s current price.

Several other equities research analysts have also commented on COLL. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 18th. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Wednesday, October 8th. HC Wainwright upped their price objective on Collegium Pharmaceutical from $44.00 to $46.00 and gave the company a “buy” rating in a research note on Friday. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 23rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Tuesday, October 28th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

Collegium Pharmaceutical Stock Up 5.3%

Collegium Pharmaceutical stock traded up $2.16 during midday trading on Friday, reaching $42.82. The stock had a trading volume of 519,932 shares, compared to its average volume of 378,437. The company has a fifty day moving average price of $35.63 and a two-hundred day moving average price of $32.65. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $43.06. The company has a current ratio of 1.18, a quick ratio of 1.10 and a debt-to-equity ratio of 3.27. The company has a market capitalization of $1.35 billion, a P/E ratio of 41.23 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. The firm had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a net margin of 5.13% and a return on equity of 97.28%. As a group, equities analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Thomas B. Smith sold 17,478 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $38.42, for a total transaction of $671,504.76. Following the completion of the transaction, the executive vice president directly owned 70,264 shares in the company, valued at $2,699,542.88. The trade was a 19.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Scott Dreyer sold 16,389 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $38.21, for a total value of $626,223.69. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at $3,959,052.73. The trade was a 13.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 44,133 shares of company stock worth $1,683,604 in the last three months. 2.51% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $244,000. Envestnet Asset Management Inc. lifted its holdings in Collegium Pharmaceutical by 26.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 30,892 shares of the specialty pharmaceutical company’s stock worth $922,000 after buying an additional 6,554 shares during the period. Emerald Mutual Fund Advisers Trust lifted its holdings in Collegium Pharmaceutical by 0.8% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 574,080 shares of the specialty pharmaceutical company’s stock worth $17,136,000 after buying an additional 4,513 shares during the period. Emerald Advisers LLC grew its position in shares of Collegium Pharmaceutical by 1.8% in the 1st quarter. Emerald Advisers LLC now owns 826,475 shares of the specialty pharmaceutical company’s stock worth $24,670,000 after buying an additional 14,795 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in shares of Collegium Pharmaceutical by 18.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company’s stock valued at $21,309,000 after buying an additional 109,655 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.